2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 3 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 13.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·59 min sittenIf the short sellers are partly to blame for today's decline of 5%. Can someone then explain to me how they know when to act? This drop must almost certainly be agreed upon.
There are different ways to place orders that test the order depth in the market (though with some uncertainty). And professional short sellers have both the experience and relatively a lot of capital. This does not necessarily mean that they are right in this case. But for the market as a whole, shorts are positive.
·3 t sitten · MuokattuCan anyone objectively explain what is driving this decline?
- ·3 t sittenShorts are back above 10% and steadily rising. H2 is set up for a blast with several crucial data sets.Phase 3 from MASH (?) is the only decisive thing, and it's probably not more "decisive" for ZP's business either. Have I overlooked other decisive datasets?
·5 t sittenNykredit writes today: Zealand Pharma (Buy) – clearly undervalued stock The company published its quarterly report yesterday and as expected, it did not trigger a significant share price reaction. The share closed with a gain of 3.7%. Overall, the financial figures were close to expectations, the year's guidance was maintained and there was no major news regarding the company's important pipeline. Management used the quarterly report as an opportunity to bolster the already large cash reserves. Pursuant to an agreement with Royalty Pharma, Zealand Pharma will receive USD 100 million for the sale of its economic interests related to the drug candidate rusfertid, including rights to a percentage royalty on potential future global sales of rusfertid as well as regulatory and commercial milestones. Of the USD 100 million, Zealand Pharma will receive an upfront payment of USD 50 million upon closing of the transaction. The remaining USD 50 million is due on the one-year anniversary of the agreement's closing. Zealand Pharma also retains the right to a 0.25% royalty on annual global net sales of rusfertid exceeding USD 1.5 billion. According to management, the amount received in connection with the agreement will be invested in pipeline projects that align more closely with the company's core areas. At the end of Q2 2026, the company's cash reserves amounted to approximately DKK 14.5 billion. Zealand Pharma and partners such as Roche and Boehringer Ingelheim are facing a number of crucial milestones for their portfolio of weight loss and diabetes drugs in the second half of 2026: Petrelintide (Amylin analog): The slow-acting amylin analog is designed to support weight loss with a focus on high tolerability. Zealand Pharma and Roche expect to initiate registrational Phase 3 studies with petrelintide as monotherapy during the second half of 2026. In addition, top-line results are expected to be published from the Phase 2 study ZUPREME-2, which investigates the effect in individuals with overweight or obesity and type 2 diabetes. Combination therapy (Petrelintide and CT-388): Concurrently, the companies are preparing to initiate the new Phase 2 study ZYNERGY in the second half of 2026. The study will investigate a fixed-dose combination of the amylin analog petrelintide and the GLP-1/GIP receptor dual inhibitor CT-388 for the treatment of overweight and obesity. Survodutide (Glucagon/GLP-1 receptor dual agonist): The development of survodutide continues with significant data on the way. Results from the Phase 3 study SYNCHRONIZE-2 will be presented at the annual congress of the European Association for the Study of Diabetes (EASD) during the period 28/9-2/10, and results from the large cardiovascular outcomes study (SYNCHRONIZE-CVOT) are also expected to be published during the second half of the year. We continue to see the stock as clearly undervalued. The cash reserves alone amount to slightly more than DKK 200 per share, while our sum-of-the-parts (SOTP) model includes a risk-adjusted discounted contribution from petrelintide of more than DKK 225 per share. All in all, our probability-adjusted SOTP valuation model points to a value of DKK 450 per share, which is also our current price target. With a 100% success rate in the company's pipeline, the model points to a value in the range of DKK 900 per share. All in all, we maintain our buy recommendation on the stock as we see an attractive risk-reward ratio.At 100% success rate... value in the range of dkk 900 per share. Analysts should read up on the blue sky scenario for petrelintide. Zealand Pharma's agreement is potentially the only one of its kind, as the upside is unusually high. Otherwise agree regarding their valuation, which is realistic - however, they have forgotten to account for the increase in cash balance that comes in Q3 (the transaction is merely booked in Q2. The cash balance thus amounts to approximately 260 dkk per share after the transaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·59 min sittenIf the short sellers are partly to blame for today's decline of 5%. Can someone then explain to me how they know when to act? This drop must almost certainly be agreed upon.There are different ways to place orders that test the order depth in the market (though with some uncertainty). And professional short sellers have both the experience and relatively a lot of capital. This does not necessarily mean that they are right in this case. But for the market as a whole, shorts are positive.
- ·3 t sitten · MuokattuCan anyone objectively explain what is driving this decline?
- ·3 t sittenShorts are back above 10% and steadily rising. H2 is set up for a blast with several crucial data sets.Phase 3 from MASH (?) is the only decisive thing, and it's probably not more "decisive" for ZP's business either. Have I overlooked other decisive datasets?
- ·5 t sittenNykredit writes today: Zealand Pharma (Buy) – clearly undervalued stock The company published its quarterly report yesterday and as expected, it did not trigger a significant share price reaction. The share closed with a gain of 3.7%. Overall, the financial figures were close to expectations, the year's guidance was maintained and there was no major news regarding the company's important pipeline. Management used the quarterly report as an opportunity to bolster the already large cash reserves. Pursuant to an agreement with Royalty Pharma, Zealand Pharma will receive USD 100 million for the sale of its economic interests related to the drug candidate rusfertid, including rights to a percentage royalty on potential future global sales of rusfertid as well as regulatory and commercial milestones. Of the USD 100 million, Zealand Pharma will receive an upfront payment of USD 50 million upon closing of the transaction. The remaining USD 50 million is due on the one-year anniversary of the agreement's closing. Zealand Pharma also retains the right to a 0.25% royalty on annual global net sales of rusfertid exceeding USD 1.5 billion. According to management, the amount received in connection with the agreement will be invested in pipeline projects that align more closely with the company's core areas. At the end of Q2 2026, the company's cash reserves amounted to approximately DKK 14.5 billion. Zealand Pharma and partners such as Roche and Boehringer Ingelheim are facing a number of crucial milestones for their portfolio of weight loss and diabetes drugs in the second half of 2026: Petrelintide (Amylin analog): The slow-acting amylin analog is designed to support weight loss with a focus on high tolerability. Zealand Pharma and Roche expect to initiate registrational Phase 3 studies with petrelintide as monotherapy during the second half of 2026. In addition, top-line results are expected to be published from the Phase 2 study ZUPREME-2, which investigates the effect in individuals with overweight or obesity and type 2 diabetes. Combination therapy (Petrelintide and CT-388): Concurrently, the companies are preparing to initiate the new Phase 2 study ZYNERGY in the second half of 2026. The study will investigate a fixed-dose combination of the amylin analog petrelintide and the GLP-1/GIP receptor dual inhibitor CT-388 for the treatment of overweight and obesity. Survodutide (Glucagon/GLP-1 receptor dual agonist): The development of survodutide continues with significant data on the way. Results from the Phase 3 study SYNCHRONIZE-2 will be presented at the annual congress of the European Association for the Study of Diabetes (EASD) during the period 28/9-2/10, and results from the large cardiovascular outcomes study (SYNCHRONIZE-CVOT) are also expected to be published during the second half of the year. We continue to see the stock as clearly undervalued. The cash reserves alone amount to slightly more than DKK 200 per share, while our sum-of-the-parts (SOTP) model includes a risk-adjusted discounted contribution from petrelintide of more than DKK 225 per share. All in all, our probability-adjusted SOTP valuation model points to a value of DKK 450 per share, which is also our current price target. With a 100% success rate in the company's pipeline, the model points to a value in the range of DKK 900 per share. All in all, we maintain our buy recommendation on the stock as we see an attractive risk-reward ratio.At 100% success rate... value in the range of dkk 900 per share. Analysts should read up on the blue sky scenario for petrelintide. Zealand Pharma's agreement is potentially the only one of its kind, as the upside is unusually high. Otherwise agree regarding their valuation, which is realistic - however, they have forgotten to account for the increase in cash balance that comes in Q3 (the transaction is merely booked in Q2. The cash balance thus amounts to approximately 260 dkk per share after the transaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 13.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
2026 Q2 -tulosraportti
UUTTA
1 päivä sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 12.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 13.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·59 min sittenIf the short sellers are partly to blame for today's decline of 5%. Can someone then explain to me how they know when to act? This drop must almost certainly be agreed upon.There are different ways to place orders that test the order depth in the market (though with some uncertainty). And professional short sellers have both the experience and relatively a lot of capital. This does not necessarily mean that they are right in this case. But for the market as a whole, shorts are positive.
- ·3 t sitten · MuokattuCan anyone objectively explain what is driving this decline?
- ·3 t sittenShorts are back above 10% and steadily rising. H2 is set up for a blast with several crucial data sets.Phase 3 from MASH (?) is the only decisive thing, and it's probably not more "decisive" for ZP's business either. Have I overlooked other decisive datasets?
- ·5 t sittenNykredit writes today: Zealand Pharma (Buy) – clearly undervalued stock The company published its quarterly report yesterday and as expected, it did not trigger a significant share price reaction. The share closed with a gain of 3.7%. Overall, the financial figures were close to expectations, the year's guidance was maintained and there was no major news regarding the company's important pipeline. Management used the quarterly report as an opportunity to bolster the already large cash reserves. Pursuant to an agreement with Royalty Pharma, Zealand Pharma will receive USD 100 million for the sale of its economic interests related to the drug candidate rusfertid, including rights to a percentage royalty on potential future global sales of rusfertid as well as regulatory and commercial milestones. Of the USD 100 million, Zealand Pharma will receive an upfront payment of USD 50 million upon closing of the transaction. The remaining USD 50 million is due on the one-year anniversary of the agreement's closing. Zealand Pharma also retains the right to a 0.25% royalty on annual global net sales of rusfertid exceeding USD 1.5 billion. According to management, the amount received in connection with the agreement will be invested in pipeline projects that align more closely with the company's core areas. At the end of Q2 2026, the company's cash reserves amounted to approximately DKK 14.5 billion. Zealand Pharma and partners such as Roche and Boehringer Ingelheim are facing a number of crucial milestones for their portfolio of weight loss and diabetes drugs in the second half of 2026: Petrelintide (Amylin analog): The slow-acting amylin analog is designed to support weight loss with a focus on high tolerability. Zealand Pharma and Roche expect to initiate registrational Phase 3 studies with petrelintide as monotherapy during the second half of 2026. In addition, top-line results are expected to be published from the Phase 2 study ZUPREME-2, which investigates the effect in individuals with overweight or obesity and type 2 diabetes. Combination therapy (Petrelintide and CT-388): Concurrently, the companies are preparing to initiate the new Phase 2 study ZYNERGY in the second half of 2026. The study will investigate a fixed-dose combination of the amylin analog petrelintide and the GLP-1/GIP receptor dual inhibitor CT-388 for the treatment of overweight and obesity. Survodutide (Glucagon/GLP-1 receptor dual agonist): The development of survodutide continues with significant data on the way. Results from the Phase 3 study SYNCHRONIZE-2 will be presented at the annual congress of the European Association for the Study of Diabetes (EASD) during the period 28/9-2/10, and results from the large cardiovascular outcomes study (SYNCHRONIZE-CVOT) are also expected to be published during the second half of the year. We continue to see the stock as clearly undervalued. The cash reserves alone amount to slightly more than DKK 200 per share, while our sum-of-the-parts (SOTP) model includes a risk-adjusted discounted contribution from petrelintide of more than DKK 225 per share. All in all, our probability-adjusted SOTP valuation model points to a value of DKK 450 per share, which is also our current price target. With a 100% success rate in the company's pipeline, the model points to a value in the range of DKK 900 per share. All in all, we maintain our buy recommendation on the stock as we see an attractive risk-reward ratio.At 100% success rate... value in the range of dkk 900 per share. Analysts should read up on the blue sky scenario for petrelintide. Zealand Pharma's agreement is potentially the only one of its kind, as the upside is unusually high. Otherwise agree regarding their valuation, which is realistic - however, they have forgotten to account for the increase in cash balance that comes in Q3 (the transaction is merely booked in Q2. The cash balance thus amounts to approximately 260 dkk per share after the transaction.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt